Literature DB >> 24494997

Humoral immune responses to HIV in the mucosal secretions and sera of HIV-infected women.

Jiri Mestecky1, Qing Wei, Rashada Alexander, Milan Raska, Jan Novak, Zina Moldoveanu.   

Abstract

Although sera and all external secretions contain antibodies to human immunodeficiency virus (HIV), their levels, specificity, isotypes, and relevant effector functions display a great degree of variability. Antibodies that bind HIV antigens and neutralize the virus are predominantly associated with the IgG isotype in sera and in all external secretions, even where total levels of IgG are much lower than those of IgA. Rectal fluid that contains high IgA, but low IgG levels, displayed low neutralizing activity independent of antibodies. Therefore, external secretions should be evaluated before and after selective depletion of Ig. At the systemic level, HIV-specific IgA may interfere with the effector functions of IgG, as suggested by recent studies of individuals systemically immunized with an experimental HIV vaccine. Although HIV-specific IgG and IgA antibodies may exhibit their protective activities at mucosal surfaces through interference with viral entry and local neutralization at the systemic level, such antibodies may display discordant effector functions.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Antibody responses; human immunodeficiency virus; mucosal immunity; secretory IgA and IgG

Mesh:

Substances:

Year:  2014        PMID: 24494997      PMCID: PMC4024328          DOI: 10.1111/aji.12203

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  59 in total

1.  Intraepithelial cell neutralization of HIV-1 replication by IgA.

Authors:  Yung T Huang; Alison Wright; Xing Gao; Lesya Kulick; Huimin Yan; Michael E Lamm
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

2.  IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects.

Authors:  M Raux; L Finkielsztejn; D Salmon-Céron; H Bouchez; J L Excler; E Dulioust; J M Grouin; D Sicard; C Blondeau
Journal:  AIDS Res Hum Retroviruses       Date:  2000-04-10       Impact factor: 2.205

3.  Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection.

Authors:  Zili Li; Senthilkumar Palaniyandi; Rongyu Zeng; Wenbin Tuo; Derry C Roopenian; Xiaoping Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

4.  Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells.

Authors:  Xugang Qiao; Bing He; April Chiu; Daniel M Knowles; Amy Chadburn; Andrea Cerutti
Journal:  Nat Immunol       Date:  2006-01-22       Impact factor: 25.606

5.  Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids.

Authors:  Shamim H Kazmi; Julian R Naglik; Simon P Sweet; Robert W Evans; Siobhan O'Shea; Jangu E Banatvala; Stephen J Challacombe
Journal:  Clin Vaccine Immunol       Date:  2006-08-23

Review 6.  Methods for evaluation of humoral immune responses in human genital tract secretions.

Authors:  Jiri Mestecky; Rashada C Alexander; Qing Wei; Zina Moldoveanu
Journal:  Am J Reprod Immunol       Date:  2010-11-19       Impact factor: 3.886

7.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

8.  Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.

Authors:  T B McNeely; M Dealy; D J Dripps; J M Orenstein; S P Eisenberg; S M Wahl
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

9.  Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.

Authors:  Jesus F Salazar-Gonzalez; Maria G Salazar; Brandon F Keele; Gerald H Learn; Elena E Giorgi; Hui Li; Julie M Decker; Shuyi Wang; Joshua Baalwa; Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; M Brad Guffey; Katharine J Bar; Katie L Davis; Christina Ochsenbauer-Jambor; John C Kappes; Michael S Saag; Myron S Cohen; Joseph Mulenga; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Martin Markowitz; Peter Hraber; Alan S Perelson; Tanmoy Bhattacharya; Barton F Haynes; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

10.  The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells.

Authors:  Sandeep Gupta; Johannes S Gach; Juan C Becerra; Tran B Phan; Jeffrey Pudney; Zina Moldoveanu; Sarah B Joseph; Gary Landucci; Medalyn Jude Supnet; Li-Hua Ping; Davide Corti; Brian Moldt; Zdenek Hel; Antonio Lanzavecchia; Ruth M Ruprecht; Dennis R Burton; Jiri Mestecky; Deborah J Anderson; Donald N Forthal
Journal:  PLoS Pathog       Date:  2013-11-21       Impact factor: 6.823

View more
  5 in total

1.  Zika virus preferentially replicates in the female reproductive tract after vaginal inoculation of rhesus macaques.

Authors:  Timothy Carroll; Ming Lo; Marion Lanteri; Joseph Dutra; Katie Zarbock; Paola Silveira; Tracy Rourke; Zhong-Min Ma; Linda Fritts; Shelby O'Connor; Michael Busch; Christopher J Miller
Journal:  PLoS Pathog       Date:  2017-07-26       Impact factor: 6.823

2.  A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.

Authors:  Sharon L Hillier; Patricia Ferrieri; Morven S Edwards; Marian Ewell; Daron Ferris; Paul Fine; Vincent Carey; Leslie Meyn; Dakota Hoagland; Dennis L Kasper; Lawrence C Paoletti; Heather Hill; Carol J Baker
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

3.  Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women.

Authors:  Nonhlanhla N Mkhize; Raveshni Durgiah; Vicki Ashley; Derseree Archary; Nigel J Garrett; Quarraisha Abdool Karim; Salim S Abdool Karim; Penny L Moore; Nicole Yates; Jo-Ann S Passmore; Georgia D Tomaras; Lynn Morris
Journal:  AIDS       Date:  2016-04-24       Impact factor: 4.177

4.  Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection.

Authors:  Milan Raska; Lydie Czernekova; Zina Moldoveanu; Katerina Zachova; Matt C Elliott; Zdenek Novak; Stacy Hall; Michael Hoelscher; Leonard Maboko; Rhubell Brown; Phillip D Smith; Jiri Mestecky; Jan Novak
Journal:  AIDS Res Ther       Date:  2014-08-01       Impact factor: 2.250

Review 5.  Challenges in mucosal HIV vaccine development: lessons from non-human primate models.

Authors:  Iskra Tuero; Marjorie Robert-Guroff
Journal:  Viruses       Date:  2014-08-15       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.